EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Interaction Between Aldosterone and Mineralocorticoid Receptor Antagonist

Masatake Kobayashi, Bertram Pitt, João Pedro Ferreira, Kevin Duarte, Faiez Zannad, Nicolas Girerd

JACC: Heart Failure · 2025-08 · 13 (8) · 102479

DOI: 10.1016/j.jchf.2025.02.025 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JACC: Heart Failure, 2025-08. Verfasst von Masatake Kobayashi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre d'Investigations Cliniques Plurithématique 1433, Inserm U1116, INSERM, CHRU de Nancy and INI-CRCT (Cardiovascular and Renal Clinical Trialists…. Hauptthemen laut MEDLINE: Mineralocorticoid Receptor Antagonists, Eplerenone, Heart Failure, Aldosterone. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Mineralocorticoid receptor antagonists (MRAs) block the activation of mineralocorticoid receptors by aldosterone, thereby mitigating cardiovascular risks. However, data on whether impact of aldosterone on outcomes differs with MRA use remain limited. OBJECTIVES: The study aims to explore the associations between baseline aldosterone, its changes and outcomes, and their interaction with eplerenone. METHODS: In a subset of the EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) trial, associations between baseline serum aldosterone concentrations, their changes from baseline to month 1, and outcomes were separately assessed in the eplerenone and placebo groups. The primary outcome was a composite of cardiovascular death or heart failure (HF) hospitalization. RESULTS: Among 453 patients (mean age: 62 ± 11 years; 75% male), baseline median serum aldosterone was 5.6 ng/dL (Q1-Q3: 3.1-9.2 ng/dL). Higher baseline serum aldosterone was associated with primary outcome in the placebo group (HR per 1 ng/dL: 1.04 ng/dL [95% CI: 1.02-1.07 ng/dL]; P = 0.002), but not in the eplerenone group (HR per 1 ng/dL: 0.99 ng/dL [95% CI: 0.93-1.05 ng/dL]; P = 0.64; P for interaction = 0.048), and these associations persisted after covariate adjustment (ie, prior HF history and renal function). At month 1, eplerenone increased serum aldosterone more than placebo (P < 0.001). High serum aldosterone changes (≥ median value) were associated with increased risk of primary outcome in the placebo group but not in the eplerenone group (HR: 3.48 [95% CI: 1.35-8.99]; P = 0.01 in placebo; HR: 0.81 [95% CI: 0.36-1.82]; P = 0.60 in eplerenone; P for interaction = 0.046), and these associations persisted after covariate adjustment. CONCLUSIONS: In patients with left ventricular systolic dysfunction and/or HF after myocardial infarction, higher baseline or rising aldosterone levels were associated with increased risk of HF events. However, eplerenone mitigated aldosterone-associated risks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mineralocorticoid Receptor AntagonistsEplerenoneHeart FailureAldosteroneSpironolactoneHumansMaleMiddle AgedFemaleAgedMyocardial InfarctionHospitalizationDouble-Blind Method

Stichwörter der Autor:innen

aldosteroneeplerenoneheart failuremineralocorticoid receptor antagonistmyocardial infarctionprognosis

Substanzen

Mineralocorticoid Receptor AntagonistsEplerenoneAldosteroneSpironolactone

Autor:innen und Institutionen

  • Centre d'Investigations Cliniques Plurithématique 1433, Inserm U1116, INSERM, CHRU de Nancy and INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network, Université de Lorraine, Nancy, France; Department of…
  • Department of Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.
  • Centre d'Investigations Cliniques Plurithématique 1433, Inserm U1116, INSERM, CHRU de Nancy and INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network, Université de Lorraine, Nancy, France; Cardiovascula…
  • Centre d'Investigations Cliniques Plurithématique 1433, Inserm U1116, INSERM, CHRU de Nancy and INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network, Université de Lorraine, Nancy, France.
  • Centre d'Investigations Cliniques Plurithématique 1433, Inserm U1116, INSERM, CHRU de Nancy and INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network, Université de Lorraine, Nancy, France. Electronic ad…

Zitieren

APA

Kobayashi, M., Pitt, B., Ferreira, J. P., Duarte, K., Zannad, F., & Girerd, N. (2025). Interaction Between Aldosterone and Mineralocorticoid Receptor Antagonist. JACC: Heart Failure, 13(8), 102479. https://doi.org/10.1016/j.jchf.2025.02.025

Vancouver

Kobayashi M, Pitt B, Ferreira JP, Duarte K, Zannad F, Girerd N. Interaction Between Aldosterone and Mineralocorticoid Receptor Antagonist. JACC: Heart Failure. 2025;13(8):102479. doi:10.1016/j.jchf.2025.02.025

BibTeX
@article{Kobayashi2025,
  author = {Kobayashi, Masatake and Pitt, Bertram and Ferreira, João Pedro and Duarte, Kevin and Zannad, Faiez and Girerd, Nicolas},
  title = {Interaction Between Aldosterone and Mineralocorticoid Receptor Antagonist},
  journal = {JACC: Heart Failure},
  year = {2025},
  volume = {13},
  number = {8},
  pages = {102479},
  doi = {10.1016/j.jchf.2025.02.025}
}
Kostenlos starten →